The New Drugs Plan Sponsors Need to Watch For
Update: 2024-02-13
Description
Host Scott Draeger welcomes Optum Rx Vice President of Trend Insights & Analytics Michelle Kamprath and Optum Rx Senior Director of Drug Pipeline & Surveillance Bill Dreitlein for a lively discussion of the year ahead in pharmacy.
Find out which trends are expected to make noise in 2024 including the ongoing obesity drug dilemma facing plan sponsors, the impact of the profusion of biosimilars on drug costs, and some noteworthy drug candidates currently advancing through the pipeline.
Find out which trends are expected to make noise in 2024 including the ongoing obesity drug dilemma facing plan sponsors, the impact of the profusion of biosimilars on drug costs, and some noteworthy drug candidates currently advancing through the pipeline.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
